Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays
Abstract
Compared with other serum polypeptides, autoantibodies have many appealing features as biomarkers including sensitivity, stability, and easy detection. Anti-lipid autoantibodies are routinely used in the diagnosis of autoimmune disease, but their potential for cancer diagnosis has not been explored. Dysregulation of cellular signaling in cancer cells would be expected to lead to irregular metabolism of many lipids, which could be sensed by immune system and cause the production of novel autoantibodies. Indeed, recent reports describe anti-lipid antibody production in cancer patients. Our hypothesis is that a broad and irregular change in lipid profiles in breast cancer cells results in the production of anti-lipid antibodies that could be used as biomarkers for early diagnosis. We propose to generate arrayed lipids on the membranes (lipid microarrays), and use them to examine global anti-lipid profiles at different stages of carcinogenesis in a transgenic breast cancer model. We have successfully set up the technology for lipid microarrays in our laboratory. Using fluorescently labeled secondary antibodies and an internal control labeled with a different fluorophor, we have greatly improved the sensitivity and reproducibility compared to the first generation of lipid microarrays. We are currently collecting more serum from newly bred mice at different ages.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2007
- Accession Number
- ADA475328
Entities
People
- Guangwei Du
Organizations
- State University of New York